Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs

Gastrointestinal Toxicity ◽

Cancer Resistance ◽

Protein Inhibitors ◽

Pharmaceutical Excipients ◽

Camptothecin Analogs ◽

Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients

International Journal of Pharmaceutics ◽

10.1016/j.ijpharm.2008.12.005 ◽

2009 ◽

Vol 370 (1-2) ◽

pp. 216-219 ◽

Cited By ~ 20

Author(s):

Tetsuo Yamagata ◽

Mariko Morishita ◽

Hiroyuki Kusuhara ◽

Kozo Takayama ◽

Hassan Benameur ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Pharmaceutical Excipients ◽

Marine Natural Products as Breast Cancer Resistance Protein Inhibitors

Marine Drugs ◽

10.3390/md13042010 ◽

2015 ◽

Vol 13 (4) ◽

pp. 2010-2029 ◽

Cited By ~ 27

Author(s):

Lilia Cherigo ◽

Dioxelis Lopez ◽

Sergio Martinez-Luis

Keyword(s):

Breast Cancer ◽

Natural Products ◽

Marine Natural Products ◽

Cancer Resistance ◽

Protein Inhibitors ◽

Nonprenylated Rotenoids, a New Class of Potent Breast Cancer Resistance Protein Inhibitors

Journal of Medicinal Chemistry ◽

10.1021/jm061450q ◽

2007 ◽

Vol 50 (8) ◽

pp. 1933-1938 ◽

Cited By ~ 60

Author(s):

Abdelhakim Ahmed-Belkacem ◽

Sira Macalou ◽

Francesca Borrelli ◽

Raffaele Capasso ◽

Ernesto Fattorusso ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Protein Inhibitors ◽

New Class ◽

FLAVONOIDS CHRYSIN AND BENZOFLAVONE, POTENT BREAST CANCER RESISTANCE PROTEIN INHIBITORS, HAVE NO SIGNIFICANT EFFECT ON TOPOTECAN PHARMACOKINETICS IN RATS OR MDR1A/1B (–/–) MICE

Drug Metabolism and Disposition ◽

10.1124/dmd.104.002501 ◽

2004 ◽

Vol 33 (3) ◽

pp. 341-348 ◽

Cited By ~ 62

Author(s):

Shuzhong Zhang ◽

Xiaodong Wang ◽

Kazuko Sagawa ◽

Marilyn E. Morris

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Protein Inhibitors ◽

Resistance Protein ◽

Pharmacokinetics In Rats

Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter

Journal of Pharmaceutical Sciences ◽

10.1016/j.xphs.2018.07.011 ◽

2018 ◽

Vol 107 (11) ◽

pp. 2946-2956 ◽

Cited By ~ 5

Author(s):

Kasirawat Sawangrat ◽

Masaki Morishita ◽

Kosuke Kusamori ◽

Hidemasa Katsumi ◽

Toshiyasu Sakane ◽

...

Keyword(s):

Breast Cancer ◽

Intestinal Transport ◽

Cancer Resistance ◽

Pharmaceutical Excipients ◽

Symmetric Bis-chalcones as a New Type of Breast Cancer Resistance Protein Inhibitors with a Mechanism Different from That of Chromones

Journal of Medicinal Chemistry ◽

10.1021/jm401879z ◽

2014 ◽

Vol 57 (7) ◽

pp. 2930-2941 ◽

Cited By ~ 29

Author(s):

Evelyn Winter ◽

Patrícia Devantier Neuenfeldt ◽

Louise Domeneghini Chiaradia-Delatorre ◽

Charlotte Gauthier ◽

Rosendo Augusto Yunes ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Protein Inhibitors ◽

New Type ◽

Faculty Opinions recommendation of The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13353972.14725070 ◽

2011 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Proximal Tubule ◽

Apical Membrane ◽

Human Kidney ◽

Cancer Resistance ◽

Kidney Proximal Tubule ◽

Faculty Opinions recommendation of Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3171959.2859057 ◽

2010 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Active Efflux ◽

P Glycoprotein ◽

Resistance Protein ◽

The Brain

Faculty Opinions recommendation of Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725783242.793517907 ◽

2016 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

Glycoprotein P ◽

Alk Inhibitor ◽

P Glycoprotein ◽

Faculty of 1000 evaluation for The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.9419956.10057054 ◽

2011 ◽

Author(s):

Robert Fecik

Keyword(s):

Breast Cancer ◽

Cancer Resistance ◽

P Glycoprotein ◽